Veraxa Biotech starts cell line development with ATUM for cancer therapy Jul 2, 2026 07:00AM
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program Jul 2, 2026 07:00AM
VERAXA Biotech expands lab space at Heidelberg R&D site Jun 24, 2026 07:00AM
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development Jun 24, 2026 07:00AM
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development Jun 24, 2026 07:00AM


Jun 18, 2026 07:02AM VERAXA Biotech reports in vitro data for its BiTAC-ADC platform
Jun 18, 2026 07:00AM VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
Jun 10, 2026 04:15PM VERAXA Biotech completes merger, begins NASDAQ trading
Jun 10, 2026 04:15PM VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026